



# JPM CBRN MEDICAL COVID-19 DIAGNOSTIC CAPABILITY: CEPHEID GENEXPERT

The JPM CBRN Medical aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation's biodefense response capability.

## OVERVIEW

The DOD, in conjunction with HHS' Biomedical Advanced Research and Development Authority (BARDA), collaborated with Cepheid, Inc. to develop a rapid diagnostic test to detect COVID-19. The test is used on Cepheid's GeneXpert diagnostic platforms, which are used worldwide to test for other infections, such as tuberculosis, HIV, Group A Streptococcus (strep), and influenza. The COVID-19 test, which received an Emergency Use Authorization (EUA) from the FDA on March 20, 2020 allowing for its immediate use, can provide results within 45 minutes and is designed for use in clinical and hospital laboratories. The JPEO-CBRND has been working with Cepheid, Inc. prior to the outbreak on the development of the Next Generation Diagnostics System 2 (NGDS 2), a Man-Portable Diagnostic System (MPDS) that meets the DOD's requirement for diagnostic equipment portable and rugged enough for use in austere military environments.

## WHY DOES DOD NEED THIS?

- Allows for the rapid diagnosis of COVID-19 cases and may prevent virus spread among DOD personnel who often operate in close quarters; avoiding large numbers of infected service members preserves readiness and strengthens national security
- Availability of diagnostic equipment and tests in DOD Medical Treatment Facilities provides the capability to care for active duty service members, beneficiaries, and retirees, lessening the burden on the civilian health care system
- Supports the timely testing of National Guard Bureau personnel who are postured to assist with COVID-19 testing in the most stressed areas of the U.S., and therefore at increased risk of contracting the virus

## WHY THE JPEO-CBRND?

- Focal point for development, acquisition, fielding, and life cycle support of chemical and biological defense equipment and FDA-approved medical countermeasures, with a proven track record of providing essential diagnostic capability to the Joint Force
- Has obligated and managed funding for the development of diagnostic systems and tests that DOD relies on to quickly and accurately diagnose a variety of chemical, biological, and endemic disease threats since 2012



GX 4



GX 16

**"WE ARE EXTREMELY PLEASED TO ASSIST BARDA IN OUR NATION'S EFFORT TO PROVIDE COVID-19 NOVEL OR EMERGING CORONAVIRUS DIAGNOSTIC TESTS TO OUR NATION'S HEALTHCARE PROVIDERS AND PUBLIC HEALTH OFFICIALS" - MR. DOUGLAS BRYCE**

## Government Partners

- Department of Defense (DOD)
- United States Army
- U.S. Department of Health and Human Services (HHS)
- Biomedical Advanced Research Development Authority (BARDA)

## Industry Partners

- Cepheid, Inc.